Literature DB >> 19596174

Clinical utility of the modified segmental boost technique for treatment of the pelvis and inguinal nodes.

M S Moran1, W A Castrucci, M Ahmad, H Song, M W Lund, S Mani, Daniel Chamberlain, S A Higgins.   

Abstract

PURPOSE: Low-lying pelvic malignancies often require simultaneous radiation to pelvis and inguinal nodes. We previously reported improved homogeneity with the modified segmental boost technique (MSBT) compared to that with traditional methods, using phantom models. Here we report our institutional clinical experience with MSBT. METHODS AND MATERIALS: MSBT patients from May 2001 to March 2007 were evaluated. Parameters analyzed included isocenter/multileaf collimation shifts, time per fraction (four fields), monitor units (MU)/fraction, femoral doses, maximal dose relative to body mass index, and inguinal node depth. In addition, a dosimetric comparison of the MSBT versus intensity modulated radiation therapy (IMRT) was conducted.
RESULTS: Of the 37 MSBT patients identified, 32 were evaluable. Port film adjustments were required in 6% of films. Median values for each analyzed parameter were as follows: MU/fraction, 298 (range, 226-348); delivery time, 4 minutes; inguinal depth, 4.5 cm; volume receiving 45 Gy (V45), 7%; V27.5, 87%; body mass index, 25 (range, 16.0-33.8). Inguinal dose was 100% in all cases; in-field inhomogeneity ranged from 111% to 118%. IMRT resulted in significantly decreased dose to normal tissue but required more time for treatment planning and a higher number of MUs (1,184 vs. 313 MU).
CONCLUSIONS: In our clinical experience, the mono-isocentric MSBT provides a high degree of accuracy, improved homogeneity compared with traditional techniques, ease of simulation, treatment planning, treatment delivery, and acceptable femoral doses for pelvic/inguinal radiation fields requiring 45 to 50.4 Gy. In addition, the MSBT delivers a relatively uniform dose distribution throughout the treatment volume, despite varying body habitus. Clinical scenarios for the use of MSBT vs. intensity-modulated radiation therapy are discussed. To our knowledge, this is the first study reporting the utility of MSBT in the clinical setting. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 19596174     DOI: 10.1016/j.ijrobp.2009.02.066

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  2 in total

1.  Radiotherapy for vaginal cancer: a multi-institutional survey study of the Japanese Radiation Oncology Study Group.

Authors:  Hitoshi Ikushima; Masaru Wakatsuki; Takuro Ariga; Yuko Kaneyasu; Sunao Tokumaru; Fumiaki Isohashi; Noriko Ii; Takashi Uno; Tatsuya Ohno; Kokichi Arisawa; Takafumi Toita
Journal:  Int J Clin Oncol       Date:  2017-10-30       Impact factor: 3.402

2.  Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of vulvar cancer and vaginal cancer.

Authors:  Toshiaki Saito; Tsutomu Tabata; Hitoshi Ikushima; Hiroyuki Yanai; Hironori Tashiro; Hitoshi Niikura; Takeo Minaguchi; Toshinari Muramatsu; Tsukasa Baba; Wataru Yamagami; Kazuya Ariyoshi; Kimio Ushijima; Mikio Mikami; Satoru Nagase; Masanori Kaneuchi; Nobuo Yaegashi; Yasuhiro Udagawa; Hidetaka Katabuchi
Journal:  Int J Clin Oncol       Date:  2017-11-20       Impact factor: 3.402

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.